Clinical Trial Update: The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update investigates the prognostic impact of high-dose hydralazine in patients with severe systolic heart failure and hemodynamically s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mitral Regurgitation
• Systolic Heart Failure

Drugs mentioned

• hydralazine (high-dose) (hydralazine)

Snippet

Sponsor: Kaohsiung Veterans General Hospital. | Conditions: Systolic Heart Failure Stage D (Disorder), Mitral Regurgitation | Phase 4 | Status: UNKNOWN